New trends in anticoagulant therapy

Israel Medical Association Journal

Volumn 6, Issue 8, 2004, Pages 479-481

  Pengo, Vittorio ^a   Pegoraro, Cinzia ^a   Iliceto, Sabino ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Anticoagulants; Atrial fibrillation; Bleeding; Drugs; Thrombosis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PENTASACCHARIDE; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CORONARY ARTERY OBSTRUCTION; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; LIVER DYSFUNCTION; LUNG EMBOLISM; POSTOPERATIVE THROMBOSIS; REVIEW; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION DISORDERS; HALF-LIFE; HUMANS; OLIGOSACCHARIDES; POLYSACCHARIDES;

EID: 4444365103     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Koopman MM, Buller HR. Short- and long-acting synthetic pentasaccharides. J Intern Med 2003;254(4):335-42.
2. Olson ST, Biork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement, J Biol Chem 1992;267(18):12528-38.
3. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162(16):1833-40.
4. Eriksson BI, Lassen MR. Pentasaccharide in hip-fracture surgery plus investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip-fracture surgery: a multicenter randomised placebo-controlled study, double-blind study. Arch Intern Med 2003; 163:1337-42.
5. Buller HR, Davidson BL, Decousus H, et al., for the Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702.
6. Coussement PK, Bassand JP, Convens C, et al., for the PENTALYSE investigators. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 200122(18):1716-24.
7. Bijsterveld NR, Vink R, Van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124(5):653-8.
8. PERSIST investigators. A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis, a phase II evaluation. Blood 2002:100:115.
9. Eriksson UG, Bredberg U, Hoffman K-J, et al. Absorption, distribution, metabolism and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs and humans. Drug Metab Dispos 2003;31:294-305.
10. Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146( 3):431-8.
11. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximalagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362:1691-8
12. Brendan M, Duggan H, Dyson J, Wright PE. Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. Eur J Biochem 1999;265:539-48.
13. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001;104(1):74-8.
14. Moons AH, Peters RJ, Bijsterved NR, et al. Recombinant nematode recombinant protein c2, an inhibitor of the tissue factor/VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 2003;41:2147-53.